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Summary
Osteoporosis is a highly prevalent disorder in the older population. The approach in management is towards
identification of high risk patients for preventive and therapeutic measures. The diagnosis of osteoporosis and
assessment of fracture risk can be made readily by measurement of bone mass with bone densitometry. Quantitative
ultrasonometry is becoming popular as an initial test to identify patients who require further investigation. Coupled
with the assessment of risk factors for osteoporosis, the use of bone mineral density can achieve high sensitivity and
specificity in identifying subjects with high fracture risk. The role of hormone replacement therapy, selective oestrogen
receptor modulators and other anti-resorptive agents such as bisphosphonates, calcitonin and vitamin D in treatment
of osteoporosis are discussed. (HK Pract 1999;21:3-10)
(BMD)
Introduction
Osteoporosis is a sys temic
skeletal disease characterised by low
bone mass and microarchitectural
deterioration of bone tissue, with a
consequent increase in bone fragility
and susceptibility to fracture.
In the past, we often described
osteoporosis as a silent disease. It
did not reveal itself until it resulted
in a fracture. But today it can be
reliably diagnosed through radiology
before fractures occur.
Causes of bone loss
The major cause of bone loss in
women is oestrogen withdrawal
associated with menopause. After
attainment of peak bone mass, the
average annual rate of bone loss is 1-
2% in postmenopausal women and
0.2-0.5% in men. The loss is greatest
in the early years after menopause,
when annual rates of loss may be up
to 3-5%. An additional increase in
bone loss may occur after the age of
70 years. Epidemiology studies
revealed a number of risk factors
associated with increased bone loss
and f rac ture risk (Table 1) in
postmenopausal women. According
to the EPIDOS study, these clinical
risk factors are very useful in
identifying subjects with low bone
mass.1 Using a 19 point scoring
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s y s t e m , a score of > 4 had a
sensi t ivi ty of 93% in ident i fy ing
subjects with low bone mine ra l
density (BMD) with a specificity of
61%.
T h e p a t h o g e n e s i s o f
osteoporosis in men is less well
established. Most have secondary
c a u s e s i n c l u d i n g a n d r o g e n
insufficiency.
Assessment of fracture risk
using BMD
Many factors determine the
likelihood of fracture, i n c l u d i n g
various skeletal abnormalities and
non-skeletal considerations, such as
falls. However, bone mass is perhaps
the most important factor and is
c e r t a i n l y the factor that can be
q u a n t i f i e d w i t h p r e c i s i o n .
Consequently, both the diagnosis of
osteoporosis and the assessment of
fracture risk centered around bone
mass measurement.
For diagnostic purposes, the
WHO study group on assessment of
fracture risk has proposed a threshold
of BMD based on the T-score. The
T-score reflects standard deviation
(SD) from a young healthy a d u l t
population. A T-score of above-1 is
considered normal and a score of -1
to -2.5 denotes low bone mass (or
osteopenia). A T-score of -2.5 or
less denotes osteoporosis. Estab-
lished osteoporosis is defined as a
T-score of -2.5 or less, with at least
one documented fragility fracture,
usually of the wrist, spine or hip.
BMD thresholds for osteoporo-
sis in men have not been well studied
but a similar absolute value to that
used in women may be applicable. A
normal BMD does not guarantee a
fracture will not occur, only that the
risk is lower. Similarly, BMD in the
osteoporotic range indicates that
f r a c t u r e s a r e l i k e l y , b u t n o t
inevitable.
T h e r i s k o f f r a c t u r e
approximately doubles for each 1 SD
Table 1: Risk factors for osteoporosis
* age .
* low body mass
* oestrogen deficiency
* maternal history of fragility fracture
* low calcium intake
* inactivity
* smoking
* caffeine
* alcohol
* gastric surgery
* medications (e.g. glucocorticoid, thyroxine, phenytoin)
decrease in BMD. Thus, the risk is
increased more than four-fold in
individuals with osteoporosis. It is
doubled again in patients who have
already had a fragility fracture. At
the age of 50 years, the average life-
time risk of the usual osteoporotic
f rac tures among white people is
approximately 13% in men and 40%
in women. For Chinese women in
Hong Kong, the cumulative life-time
risk of having osteoporotic fractures
is 25%.2
Techniques used to measure
bone mass
Bone densitometry
Bone mass is usually measured
u s i n g s i n g l e - o r d u a l - e n e r g y
absorp t iomet ry . S ing l e - ene rgy
absorptiometry (SXA) is used to
measure bone mass at peripheral
(appendicular) sites including the
heel and wrist. Bone mass at axial
sites such as the spine and hip (where
fractures often occur) cannot be
accura te ly measured wi th SXA,
necessitating the use of dual-energy
absorp t iomet ry . Ei ther photons
(DPA) or X-rays (DXA) can be used.
Frequently measured sites included
the hip, spine and forearm.4 In Hong
Kong, DXA is more widely available
than DPA. Figure 1 and Table 2
show a typical dual energy X-ray
absorptiometry (DEXA) scan of the
l u m b a r sp ine and i t s a n a l y s i s ,
respectively.
Quantitative ultrasonometry
Quan t i t a t ive Ul t rasonometry
(QUS) is becoming more popular
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Figure 1: Dual energy X-ray absorptiometry (DEXA)
scan of the lumbar spine in an osteoporotic
patient
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because it is cheap, radiation free,
non- invas ive and portable. QUS
measures the broadband ultrasound
attenuation and speed of sound as the
ultrasound hits or passes through the
bone. Some machines provide a
stiffness index derived from these
two parameters. Numerous studies
h a v e d e m o n s t r a t e d t h a t u l t r a -
sonometry of the heel, using both
contact and water-based devices, has
h i g h p r e d i c t i v e a c c u r a c y f o r
fracture.5 Prospective studies using
water-based ultrasonometers show
that heel ultrasound can predict the
risk of fractures of both the spine and
proximal femur in women over 70.
T h e r e l a t i v e r i s k b a s e d o n
measurement of the stiffness index is
comparable to axial BMD in these
osteoporotic fractures.6-7 There are
no prospective studies demonstrating
that the t ib ia l device predicts hip
fracture.
Other techniques
Other techniques for measuring
bone mass i n c l u d e q u a n t i t a t i v e
c o m p u t e d t o m o g r a p h y a n d
radiographic techniques. Quantita-
t i ve computed tomography has
limited clinical application due to the
h igh dose of radiat ion exposure.
Similar ly, ordinary radiographs are
inaccurate and insensitive and do not
detect bone loss until 25 - 40% of the
bone is already lost. However, this
is how o s t e o p o r o s i s is o f t e n
diagnosed.
Bone mass measurement in
clinical practice
The most accurate prediction of
fracture requires assessment of the
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site concerned. At the t ime of
menopause, BMD measurements at
the wrist, spine or hip are useful. But
measurements at the hip are more
valuable in the elderly, for whom hip
f rac tures are the common major
problem. The spine, however, may
not be suitable in the elderly because
of the presence of osteoarthritis. But
response to treatment are often more
marked at the spine than elsewhere
and can be detected earlier than at the
hip or wrist.
At present, QUS can help to
ident i fy patients who need fur ther
testing. Ultrasonometry of the os
calcis provides independent informa-
tion on risk of both spine and hip
fracture, even though the correlation
wi th BMD at these si tes is only
about 0.5 to 0.7.8 It is believed that
QUS provides information other than
bone density, such as the stiffness
and connectivity of the bone. One of
the remaining questions is the extent
to w h i c h ul t rasonometry predicts
fracture in the early post-menopausal
years. The challenge in the next few
years wi l l be the appropriate use of
ultrasonometry of the heel, especially
i ts use in m o n i t o r i n g t rea tment
efficacy. At present, the use of QUS
is limited by the poor precision and
accuracy of QUS when compared to
DEXA.
Clinical approach towards
patient identification
Mass screening of BMD is not
just i f ied as it is not cost-effective.
The use of BMD alone to assess risk
h a s h i g h s p e c i f i c i t y b u t l o w
sensi t ivi ty. The approach therefore
is towards identification of high risk
cases for therapeutic and preventive
treatment.3 The patient's history and
t h e r e s u l t s o f p h y s i c a l a n d
biochemical examinat ion should be
taken into account for decision for
BMD measurements. Some of the
indications for BMD measurement
are shown in Table 3.
Treatment of osteoporosis
The objective of all measures to
prevent and treat osteoporosis is the
same - to achieve or maintain bone
densi ty at a level that the risk of
fractures is low.
Hormone replacement therapy
(HRT)
Oestrogen is the oldest and most
common treatment for osteoporosis.
Recent reports have indicated that
over a 3-year period, women who
stayed on any HRT regimen - with or
w i t h o u t a proges togen - had an
average increase in bone density of
4% at the spine and 2% at the hip.
Those tak ing placebo registered
losses in bone densi ty averaging
1.8% at the spine and 1.7% at the
hip. 9 HRT also has a favourab le
effect on cholesterol and c lo t t ing
profiles.
The role of HRT on the bone can
be summarised as follows:
1. Oestrogen is most effective in
retarding bone loss when it is
initiated shortly after the onset of
menopause.
2. Oestrogen must be used for at
least 7 to 10 years to have an
effect on bone loss.1 0
2.
3.
4.
5.
6.
: Some indications for bone mass measurement
Presence of strong risk factors
• Premature menopause (< 45 years)
• Prolonged secondary amenorrhoea
• Primary hypogonadism
• Corticosteroid therapy
• Secondary causes for osteoporosis
Anorexia nervosa
Malabsorption
Primary hyperparathyroidism
Post-transplantation
- Chronic renal failure
Hyperthyroidism
Prolonged immobilization
Cushing's syndrome
Previous osteoporotic fracture
Radiographic evidence of osteopenia and vertebral deformity
Significant loss of height or kyphosis
Monitoring treatment efficacy
Perimenopausal and postmenopausal women who are making a decision
on preventive therapy based on BMD results
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3. Present oestrogen use is more
important than past use. Current
o e s t r o g e n u s e r s h a d a
significantly lower risk of frac-
tures than their contemporaries
who had taken oestrogen for
s e v e r a l y e a r s , b u t h a d
d i scon t inued i t many years
previously." It is clear that the
protective effect of oestrogen on
the bone will wear off once the
woman stops oestrogen.
4. Progestogen use has a minimal
effect on osteoporosis r isk.
Women who have had a hyster-
ectomy and are considering HRT
need not add a progestin for the
sake of their bones.9
HRT has been reported to be
associated with an increased risk of
breast cancer - a finding that remains
con t rover s i a l . 1 1 There was no
increase in risk associated with
taking HRT up to 5 years. HRT for
more than 5 to 10 years increases the
average woman's risk of breast
cancer by 30%. The increase in risk
seemed to disappear entirely 2 years
after HRT was discontinued.
Selective estrogen receptor modu-
lators (SERMS)
SERMS is a new group of
agents with oestrogen agonistic
action in some tissues such as the
bone, cardiovascular system, brain
and has antagonistic action in other
tissues such as uterus and breast.
The prototype of this class of drugs
is tamoxifen, which is used to treat
and prevent breast cancer. Interest
has been generated by this class of
drugs, especially in the last few years
when it was realized that oestrogen
binds to two receptors - a, the
original receptor (present in breast,
uterine endometrium, liver) and the
newly identified oestrogen receptor |3
(present in bone, blood vessels).
Because of lack of stimulatory action
on the uterus, it is unnecessary to add
on progestogens in women with an
intact uterus.
Raloxifene has been marketed in
some countries recently as an alterna-
tive to other oestrogen preparations.
Like oestrogen, Raloxifene lowers
LDL cholesterol, and has no adverse
effect on total triglyceride, although
unlike oestrogen it does not raise the
HDL cholesterol level .1 2 Results
showed tha t w i t h 24 m o n t h s of
treatment, clinical vertebral fractures
was decreased by half .1 3 Although
the bone mineral density increase
was modest (increased by 2.0% at the
hip and by 2.5% at the spine),
fracture incidence is reduced by 50%
which was similar to that from HRT
or other agents such as alendronate.
The effect on hip fracture protection
is still uncertain.
Because SERMS are selective,
and act as antagonists in the breast
tissue, evidence is mounting that they
are not associated with breast cancer
risk. With 33 months of therapy,
Raloxifene lowered the risk of breast
cancer by 70%.14
Bisphosphonates
Bisphosphonates inhibit bone
resorption by binding to mineralized
bone surfaces. Bisphosphonates may
be considered as an alternative to
HRT in postmenopausal osteoporotic
women who cannot tolerate HRT.
Compared with HRT, bisphospho-
nates are bone specific, of equal or
greater efficiency in improving bone
density and have fewer side-effects.15
The bisphosphonates are poorly
absorbed and should not be taken
with meals or calcium tablets. At
present etidronate and alendronate
are the mos t c o m m o n l y u sed
bisphosphonates.
Treatment with etidronate can
increase the lumbar spine BMD by 5
- 10% over 2 years. Vertebral fracture
risk is decreased. The effect of
et idronate on hip f racture is not
known. To avoid minera l i za t ion
defect, etidronate is given cyclically
in a dose of 400mg daily for 14 days
every 3 months. Calcium supple-
mentation is given during the rest of
the 3-month cycle when the patient is
not on etidronate. Side effects are
uncommon.
Alendronate at a dose of 10 mg
daily increased the lumbar spine
BMD by 8% and the femoral neck
BMD by 5% in three years.16 In large
r a n d o m i s e d c o n t r o l l e d t r i a l s ,
alendronate was shown to reduce
both vertebral fracture and hip frac-
ture in postmenopausal osteoporotic
women by approximately 50% in
those with and without pre-existing
vertebral fractures.17 Alendronate is
prescribed at a continuous dose of
10mg daily. At this dose it is not
k n o w n to cause mine ra l i za t ion
defect. To avoid oesphageal and
upper intestinal irritation, it must be
taken with a full glass of water at
least 30 minutes before breakfast.
Treatment with bisphosphonates
should be given for three to five
years. At present it is uncertain how
long the drug should be continued
and whether bone loss will resume
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once the drug is stopped. Apart from
p o s t m e n o p a u s a l o s t eopo ros i s ,
bisphonates are also useful in treating
steroid-induced bone loss. There are
ongoing trials to evaluate the use of
bisphosphonates in treating male
osteoporosis.
Calcitonin
C a l c i t o n i n i n h i b i t s b o n e
resorption by inhibi t ing osteoclast
activity. Small scale studies showed
significant improvement in BMD in
postmenopausal women.18 Long-
term effects of calcitonin on fracture
prevention are not available. A large
scale prospective study is currently
ongo ing to address t h i s i ssue .
Current evidence does not support its
use as a f i rs t l ine t reatment for
established osteoporosis. Its use is
also limited by cost consideration.
Calcitonin is given either by parental
in jec t ion (50 to 100 IU da i ly or
100 IU three times per week given
intramuscularly or subcutaneously)
or as a nasal spray (200 IU daily).
When given parental ly, calcitonin
may cause nausea , f l u s h i n g and
g a s t r o i n t e s t i n a l upse t . N a s a l
c a l c i t o n i n m a y r e s u l t i n n a s a l
irritation.
In addition to preventing bone
loss, calci tonin also has analgesic
effect and can reduce acute pain
associated with vertebral fractures.19
T h e r a p y s h o u l d b e a d j u s t e d
according to response and may be
effective for at least one month.
Vitamin D
The use of vi tamin D and its
der iva t ives in the t r e a t m e n t of
osteoporosis is controversial. With
the sufficient sunlight in Hong Kong,
it is unnecessa ry to recommend
vi t amin D for everyone. For the
elderly who are institutionalized may
be at risk of vitamin D insufficiency,
supplementation of vitamin D of 400
to 800 IU per day is recommended.
It has been shown that vitamin D is
not useful in preventing hip fractures
in ambulatory community-dwel l ing
postmenopausal women, but is able
t o r e d u c e h i p f r a c t u r e s i n
inst i tut ionalized subjects.20-21 The
use of vitamin D derivatives such as
1 a-vitamin D and calcitriol may be
complicated by hypercalcaemia and
hypercalciuria.
Monitoring of treatment
progress
Bone mass measurements
It is recommended to repeat
BMD by DXA studies at 2 yearly
i n t e r v a l s af ter the i n i t i a t i o n of
t r e a t m e n t . Even w i t h the best
treatment and response, there wil l
only be at most a 5-10% increase in
the bone density. Treatment induced
changes are often most marked at the
spine. Repeated assessment is not
r o u t i n e l y i n d i c a t e d i n h e a l t h y
perimenopausal or postmenopausal
w o m e n a l r e a d y t a k i n g HRT for
p r e v e n t i o n of bone loss, but is
justif ied in patients taking HRT or
other anti-resorptive agents, such as
bisphosphonates or calcitonin, who
have complicat ing factors such as
malabsorpt ion or cort icosteroid
therapy. The BMD measured with
different machines cannot be directly
compared as there are s ignif icant
differences among the methods used.
It is recommended to fo l low-up
pat ients wi th calibrated machines
from the same manufacturers. The
use of QUS in following treatment
progress awaits further validation.
Biochemical markers of bone
turnover
Treatment with anti-resorptive
a g e n t s i n p o s t m e n o p a u s a l
osteoporosis induces a 30 - 60%
decrease in biochemical markers of
bone turnover wi thin 3 to 6 months
of therapy. The acute response of
biochemical markers to treatment is
predictive of the subsequent response j
of the bone mass over 2 years, but
the lack of response of these markers
does not necessari ly mean a poor
response in BMD. Measurement of
biochemical bone markers at baseline
and after 3 to 6 months of therapy
may help to improve p a t i e n t ' s
compliance, since these treatment
effect can be detected much earlier
than changes in BMD. At present,
these b iochemical tests are not
widely available. •
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Key messages
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